leisure time -WSS

leisure time

author：explore 2025-09-06 03:16:57 - browse：172

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Readout Newsletter: Bristol, Sangamo, Gilead, and more

leisure time

WSS

Male and female sex labels in research insufficient, scientists say

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

MoonLake credibility takes another hit with mid

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Boston's new lab space is opening empty

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

hotspot

leisure time

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA approves potent Eli Lilly obesity drug, Zepbound

Jerome Adams on the need for new antivirals for Covid

UCSF medical school apologizes for unethical prisoner experiments

What does generative AI mean for health care? We asked experts

HHS secretary Becerra pressed on Change HealthCare cyberattack

Guidelines to prevent youth baseball injuries need more muscle

Senate panel clears PBM, hopsital reforms

FDA approval of Sarepta Duchenne genetic therapy gives me hope

More doctors should go into startup world

Wikipedia

Boston's new lab space is opening empty

Amid AI frenzy, a top HHS official's quest to create safeguards

STAT Executive Editor Rick Berke on STAT's 8th birthday

Victims of gun violence feel impacts long after bullet wound

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

WuXi out of biotech trade group, U.S. and China relations to blame

knowledge

knowledge

leisure time

focus